• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

lavinia.spain@unimelb.edu.au

Credentials


Position
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-9356-8812

Dr Lavinia Spain

Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology

103 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma
    DOI: 10.1001/jamanetworkopen.2026.7030
  • 2026

    Journal article

    [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
    DOI: 10.1016/S1470-2045(26)00017-3
  • 2026

    Journal article

    CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.
    DOI: 10.1200/JCO.2026.44.7_suppl.416
  • 2026

    Journal article

    Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
    DOI: 10.1016/j.eururo.2026.03.024
  • 2025

    Journal article

    Patterns of recurrence after lymphadenectomy for melanoma lymph node metastasis at high risk of recurrence in the modern era of adjuvant systemic therapy.
    DOI: 10.1016/j.ejso.2025.111135
  • 2025

    Journal article

    Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
    DOI: 10.1186/s13059-025-03812-2
  • 2025

    Journal article

    Neuroimaging features of immune-related adverse events due to immune checkpoint inhibitor therapy
    DOI: 10.1186/s13244-025-01999-3
Lavinia Spain

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
    DOI: 10.1136/jitc-2025-011865
  • 2025

    Journal article

    Long-term clinical outcomes of bevacizumab for treatment of stereotactic radiosurgery-induced radiation necrosis in patients with brain metastases
    DOI: 10.1007/s11060-025-05121-x
  • 2025

    Journal article

    1694eP Real-world induction targeted therapy (TT) with immune checkpoint inhibitor (ICI) therapy switch in advanced BRAF-mutant melanoma: A multi-institutional study
    DOI: 10.1016/j.annonc.2025.08.2321

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224